The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma (NeoPele): Analysis of tumor microenvironment (TME) correlated to pathological response.
 
Ines Esteves Domingues Pires Da Silva
Consulting or Advisory Role - MSD; MSD
 
Jordan W. Conway
No Relationships to Disclose
 
Akshaya Ramanathan
No Relationships to Disclose
 
Laura Smith
No Relationships to Disclose
 
Robert V Rawson
Honoraria - MSD
 
Piyush Grover
No Relationships to Disclose
 
Nigel Maher
No Relationships to Disclose
 
Jorja Braden
No Relationships to Disclose
 
Maria Gonzalez
No Relationships to Disclose
 
Umaimainthan Palendira
No Relationships to Disclose
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Richard A Scolyer
Employment - Sydney Local Health District / Royal Prince Alfred Hospital
Leadership - Melanoma Institute Australia
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb GesmbH (Austria); Bristol-Myers Squibb SA (Switzerland); Evaxion Biotech; GlaxoSmithKline; IO Biotech; Merck Sharp & Dohme; metaoptima; MSD Sharp & Dohme (Australia) Pty Limited; Myriad Genetics; NeraCare GmbH; Novartis; Novartis; Novartis; Novartis; Provectus Biopharmaceuticals; QBiotics; Roche
Research Funding - Melanoma Research Alliance (MRA); National Health and Medical Research Council; National Health and Medical Research Council; Tour de Cure
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron